Various immunological approaches to the control, treatment and prevention of leukaemia.
D000276:Adjuvants, Immunologic; D000818:Animals; D000921:Antibody-Producing Cells; D000951:Antigens, Neoplasm; D001215:Asparaginase / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents; D007167:Immunotherapy; D007938:Leukemia / Q000188:drug therapy / Q000276:immunology*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D011070:Poly I-C / Q000627:therapeutic use; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D007166:Immunosuppressive Agents; D014750:Vincristine; D015122:Mercaptopurine; D001215:Asparaginase; D011070:Poly I-C; D011241:Prednisone; D008727:Methotrexate